Automated Insulin Delivery Improves Glycemia, Not Yet Perinatal Outcomes

This integrative review clarifies that automated insulin delivery benefits in type 1 diabetes pregnancy are system-specific and centered on glucose metrics, giving Women's Health pharmacists a device-by-device framework for counseling and implementation.

automated insulin deliveryhybrid closed-loopCamAPS FXMiniMed 780GTandem Control-IQtype 1 diabetespregnancycontinuous glucose monitoringtime in rangeintegrative reviewhealth equityAiDAPTCRISTALCIRCUIT Women's Health / Reproductive

Background Information

Automated insulin delivery transforms diabetes management in pregnancy.

Automated insulin delivery (AID) systems have significant potential to improve glycemic control during pregnancy in individuals with type 1 diabetes, enhancing maternal and neonatal health outcomes. The review highlights system-specific evidence for improved continuous glucose monitoring outcomes with AID systems like CamAPS FX and MiniMed 780G, but notes gaps in long-term maternal and neonatal data. The study underscores the need for equitable implementation of AID systems, considering algorithm design, user interaction, and access to specialist care, while acknowledging existing evidence limitations. AID systems can significantly enhance pregnancy outcomes in type 1 diabetes, but require careful socio-technical assessment for equitable use.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Li J, Qi TN, Tan X, Jayasekara R

Citation: Li J, Qi TN, Tan X, et al. Automated Insulin Delivery in Pregnancy With Type 1 Diabetes: An Integrative Review of Clinical Evidence, Socio-Technical Implementation and Equity. Journal of diabetes research. 2026;2026(1):e1989683. doi:10.1155/jdr/1989683

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →